APP and Alzheimer disease: Given that Aβ aggregation and Tau hyperphosphorylation are hallmarks of AD and that APP, the precursor to Aβ, can be degraded via CMA [20], the effects of TBG096 on APP, Tau, p-Tau, and Aβ oligomers were evaluated.